Atara Biotherapeutics Inc. buy stratec
Start price
08.01.18
/
50%
€16.73
Target price
04.11.21
€29.17
Performance (%)
4.05%
End price
05.11.21
€17.41
Summary
This prediction ended on 05.11.21 with a price of €17.41. With a performance of 4.05%, the BUY prediction by stratec for Atara Biotherapeutics Inc. closed with a slight gain. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Atara Biotherapeutics Inc. | 2.482% | 2.482% | -72.415% | -94.200% |
| iShares Core DAX® | -0.992% | -3.231% | 11.661% | 16.545% |
| iShares Nasdaq 100 | -0.225% | -3.339% | 36.491% | 43.334% |
| iShares Nikkei 225® | -0.736% | -7.859% | 18.597% | 4.253% |
| iShares S&P 500 | -0.509% | -2.979% | 26.341% | 40.911% |
Comments by stratec for this prediction
In the thread Atara Biotherapeutics Inc. diskutieren
Atara, leader in allogeneic T-cell immunotherapy
This leader in allogeneic T-cell immunotherapy has a promising lead drug candidate and several irons in the fire.
ATA129 is being evaluated in dual pivotal studies to treat cancer patients with rituximab-refractory EBV-PTLD and has exhibited encouraging data to date.
Promising early results were observed in refractory nasopharyngeal carcinoma, and a phase 1/2 study combining ATA129 with Merck's Keytruda should be initiated soon.
ATA190 in progressive MS shouldn't be overlooked, institutional positioning bodes well, and
management has the necessary experience to get the job done.
Kursziel geändert auf 29,1712
In the thread Trading Atara Biotherapeutics Inc.
Die von stratec gewählte maximale Laufzeit wurde überschritten